利格列汀辅助治疗老年糖尿病患者的疗效分析  

Efficacy analysis of linagliptin in adjuvant treatment of senile diabetes mellitus

作　　者：花国辉 HUA Guo-hui(Department of Internal Medicine,Fushun Petrochemical General Hospital,Fushun 113000,China)

机构地区：[1]抚顺石化总医院内科,113000

出　　处：《中国实用医药》2022年第1期135-138,共4页China Practical Medicine

摘　　要：目的分析利格列汀治疗老年糖尿病患者的疗效及有效率。方法100例老年糖尿病患者,随机分为对照组和观察组,每组50例。对照组患者采取二甲双胍口服治疗,观察组给予二甲双胍联合利格列汀治疗。比较两组治疗效果、不良反应以及治疗前后的血脂指标[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、血糖指标[糖化血红蛋白(HbA1c)、空腹血糖(FBG)、餐后2 h血糖(2 h PG)]。结果观察组治疗总有效率96.00%高于对照组的80.00%,差异具有统计学意义(P<0.05)。治疗后,观察组患者TC(4.04±0.14)mmol/L、TG(1.31±0.5)mmol/L、LDL-C(2.74±0.53)mmol/L均低于对照组的(5.02±0.15)、(1.82±0.41)、(3.82±0.62)mmol/L,HDL-C(2.12±0.50)mmol/L高于对照组的(1.32±0.37)mmol/L,差异均具有统计学意义(P<0.05)。治疗后,观察组患者FBG(7.25±1.81)mmol/L、2 h PG(9.04±2.71)mmol/L、HbA1c(6.22±1.21)mmol/L均低于对照组的(9.24±2.41)、(11.15±5.29)、(8.36±1.45)mmol/L,差异均具有统计学意义(P<0.05)。两组均未出现严重不良反应。结论利格列汀辅助治疗老年糖尿病的临床效果确切,可有效调节患者血脂水平,控制血糖,改善预后,且未增加不良反应,安全性高。Objective To analyze the efficacy and efficiency of linagliptin in adjuvant treatment of senile diabetes mellitus.Methods A total of 100 senile patients with diabetes mellitus were randomly divided into control group and observation group,with 50 cases in each group.Patients in the control group were treated with metformin orally,and patients in the observation group was treated with metformin and linagliptin.Both groups were compared in terms of therapeutic effects,occurrence of adverse reactions and blood lipid indexes[triglycerides(TG),total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C)],blood glucose indicators[glycosylated hemoglobin(HbA1c),fasting blood glucose(FBG),2 h postprandial glucose(2 h PG)]before and after treatment.Results The total effective rate 96.00%in the observation group was higher than 80.00%in the control group,and the difference was statistically significant(P<0.05).After treatment,the TC(4.04±0.14)mmol/L,TG(1.31±0.5)mmol/L,and LDL-C(2.74±0.53)mmol/L of the observation group were lower than(5.02±0.15),(1.82±0.41),and(3.82±0.62)mmol/L of the control group,and the HDL-C(2.12±0.50)mmol/L was higher than(1.32±0.37)mmol/L of the control group.All the differences were statistically significant(P<0.05).After treatment,the FBG(7.25±1.81)mmol/L,2 h PG(9.04±2.71)mmol/L,and HbA1c(6.22±1.21)mmol/L of the observation group were lower than(9.24±2.41),(11.15±5.29),and(8.36±1.45)mmol/L of the control group,and the difference was statistically significant(P<0.05).No serious adverse reactions occurred in the two groups.Conclusion Linagliptin has definite clinical effect in the adjuvant treatment of senile diabetes mellitus,which can effectively regulate patients’blood lipid level,control blood glucose and improve prognosis without increasing adverse reactions,and has high safety.

关 键 词：利格列汀 老年糖尿病 疗效 

分 类 号：R587.1[医药卫生—内分泌]